Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the company's partners make progress developing and commercializing their products being developed with ENHANZE®. 

We are a diverse team, who are committed to bringing therapies and results to patients. It's not enough to be qualified and experienced at what you do, we are looking for people who believe in our mission and match our values. 

We are building a company where people can pursue their career goals in a supportive and collaborative team environment. Visit www.halozyme.com/careers for more details.   

We are Halozyme. 



Silicon Valley Bank

Oxford Finance LLC

Pharmakon Advisors

Athyrium Capital Management LP

Janssen Biotech

argenx

Halozyme, Inc.

We are excited to announce that Halozyme and Acumen Pharmaceuticals, Inc. have entered a global collaboration and non-exclusive license agreement for the ENHANZE® technology in Alzheimer’s disease.

This partnership presents an exceptional opportunity to provide additional treatment options to patients with Alzheimer's disease. According to the World Health Organization, over 55 million people suffer from dementia worldwide, and Alzheimer's disease can be attributed to 60-70% of cases. 

Our collaboration reinforces our commitment to provide innovative solutions to improve the patient treatment experience, particularly for such a challenging disease in a large patient population.

https://ow.ly/Hyyl50Q65fy

Halozyme recently reported our third quarter 2023 financial and operating results, including a 15% year-over-year increase in royalty revenue to a record $114.4 million.

"The third quarter was remarkable, with multiple, meaningful, de-risking events and progress for our upcoming series of Wave 3 potential product launches, projected for 2023-2025. I am also pleased with the progress in advancing discussions on development of our HVAI." - Dr. Helen Torley, president and CEO of Halozyme.

We are delighted with our strong operating performance and expense management throughout the year and will continue to work toward achieving our 2023 financial and operational goals.

#Halozyme

https://ow.ly/sFcF50Q659y

Join us and our men’s health experts on Friday, November 17, 2023, for a live product theater at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting in San Diego to learn about different auto-injection and oral delivery testosterone replacement therapy options. 

We hope to see you there! 

#Halozyme #SMSNA23 #TRT #MensHealth

Subcutaneous (SC) infusion is a promising way to deliver drugs, but the volume and viscosity of solutions that can be administered subcutaneously are limited by the inability of fluids to flow in the SC space. 

Recent research looks a little closer at how recombinant human hyaluronidase PH20 (rHuPH20) can help overcome volume and time constraints associated with SC administrations across various concentrations.

Read the research here: https://bit.ly/46KpdUW

#Subcutaneous #DrugDelivery


Halozyme aims to innovate in delivery technology for transformative therapies. 

With innovation and dedication, our mission includes simplifying treatment procedures and reducing the time required for therapies, with subcutaneous drug delivery. 

Through our efforts, Halozyme aims to empower both healthcare providers and patients by providing potentially life-changing drug delivery solutions. 

https://bit.ly/3LYJka5

#Halozyme #subcutaneousdrugdelievry

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	54.80M -	75.33M 37.47%	135.06M 79.28%	146.69M 8.61%	316.61M 115.84%	151.86M 52.04%	195.99M 29.06%	267.59M 36.53%	443.31M 65.67%	660.12M 48.91%	829.25M 25.62%
cost of revenue	6.25M -	22.73M 263.96%	29.25M 28.65%	33.21M 13.54%	31.15M 6.19%	10.14M 67.46%	45.55M 349.35%	43.37M 4.78%	81.41M 87.73%	139.30M 71.11%	192.36M 38.09%
gross profit	48.55M -	52.60M 8.34%	105.81M 101.16%	113.48M 7.25%	285.46M 151.54%	141.73M 50.35%	150.45M 6.15%	224.23M 49.04%	361.90M 61.40%	520.81M 43.91%	636.89M 22.29%
selling and marketing expenses
general and administrative expenses	32.35M -	35.94M 11.11%	40.03M 11.37%	45.85M 14.55%	53.82M 17.37%	60.80M 12.98%
selling general and administrative expenses	32.35M -	35.94M 11.11%	40.03M 11.37%	45.85M 14.55%	53.82M 17.37%	60.80M 12.98%	77.25M 27.05%	45.74M 40.80%	50.32M 10.03%	143.53M 185.21%	149.18M 3.94%
research and development expenses	96.64M -	79.70M 17.53%	93.24M 16.99%	150.84M 61.79%	150.64M 0.13%	150.25M 0.26%	140.80M 6.29%	34.24M 75.69%	35.67M 4.19%	66.61M 86.72%	76.36M 14.65%
other expenses										43.15M -	73.77M 70.98%
cost and expenses	135.23M -	138.37M 2.32%	162.51M 17.45%	229.90M 41.47%	235.61M 2.48%	221.19M 6.12%	263.60M 19.17%	123.34M 53.21%	167.41M 35.73%	392.58M 134.51%	491.68M 25.24%
operating expenses	128.99M -	115.64M 10.35%	133.26M 15.24%	196.69M 47.60%	204.46M 3.95%	211.06M 3.23%	218.06M 3.32%	79.97M 63.33%	86.00M 7.53%	253.28M 194.53%	299.32M 18.18%
interest expense	3.27M -	5.58M 70.46%	5.20M 6.81%	19.98M 284.10%	21.98M 10.05%	18.04M 17.94%	11.63M 35.55%	20.38M 75.26%	7.53M 63.07%	16.95M 125.18%	18.76M 10.71%
ebitda	-80.43M -	-63.04M 21.63%	-27.45M 56.45%	-83.21M 203.11%	81.00M 197.35%	-69.33M 185.59%	-67.61M 2.48%	144.25M 313.36%	275.90M 91.26%	310.68M 12.60%	422.43M 35.97%
operating income	-80.43M -	-63.04M 21.63%	-27.45M 56.45%	-83.21M 203.11%	81.00M 197.35%	-69.33M 185.59%	-67.61M 2.48%	144.25M 313.36%	275.90M 91.26%	267.53M 3.03%	337.57M 26.18%
depreciation and amortization	1.23M -	1.76M 43.61%	1.68M 4.82%	2.41M 43.71%	2.16M 10.33%	2.39M 10.50%	4.07M 70.35%	3.28M 19.27%	3.00M 8.74%	43.15M 1,339.71%	84.86M 96.66%
total other income expenses net	229.23K -	242K 5.57%	422K 74.38%	1.33M 214.22%	2.59M 95.48%	7.58M 192.36%	-4.64M 161.24%	-14.95M 222.19%	-27.38M 83.13%	-18.61M 32.03%	29.52M 258.58%
income before tax	-83.48M -	-68.38M 18.09%	-32.23M 52.86%	-101.86M 216.03%	61.61M 160.48%	-79.79M 229.51%	-72.25M 9.45%	129.30M 278.96%	248.52M 92.20%	248.92M 0.16%	348.33M 39.94%
income tax expense	2.05M -	3.82M 86.55%	3.52M 7.72%	1.16M 67.03%	-1.36M 217.13%	537K 139.46%	-11K 102.05%	217K 2,072.73%	-154.19M 71,156.22%	46.79M 130.34%	66.73M 42.63%
net income	-83.48M -	-68.38M 18.09%	-32.23M 52.86%	-103.02M 219.64%	62.97M 161.12%	-80.33M 227.57%	-72.24M 10.07%	129.09M 278.69%	402.71M 211.97%	202.13M 49.81%	281.59M 39.31%
weighted average shs out	112.81M -	122.69M 8.76%	126.70M 3.27%	127.96M 0.99%	136.42M 6.61%	143.60M 5.26%	144.33M 0.51%	136.21M 5.63%	140.65M 3.26%	136.84M 2.70%	131.93M 3.59%
weighted average shs out dil	112.81M -	122.69M 8.76%	126.70M 3.27%	127.96M 0.99%	139.07M 8.68%	143.60M 3.26%	144.33M 0.51%	141.46M 1.99%	146.80M 3.77%	140.61M 4.22%	134.20M 4.56%
eps	-0.74 -	-0.56 24.32%	-0.25 55.36%	-0.81 224.00%	0.46 156.79%	-0.56 221.74%	-0.50 10.71%	0.95 290%	2.86 201.05%	1.48 48.25%	2.13 43.92%
epsdiluted	-0.74 -	-0.56 24.32%	-0.25 55.36%	-0.81 224.00%	0.45 155.56%	-0.56 224.44%	-0.50 10.71%	0.91 282%	2.74 201.10%	1.44 47.45%	2.10 45.83%

COM:HALOZYME

Halozyme Therapeutics, Inc.

Last Close

45.70

22/11 21:00

Market Cap

6.74B

Beta: -

Volume Today

4.55M

Avg: -

Preview